Delivery Order SPE2DB20D3103-SPE2DB25FM8R3

Award Date 2/26/25
Potential Completion Date 2/27/25
Potential Value $2.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $28,756.98 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The order is for the supply of XIFAXAN 550 MG TABLET 60S, a medication used to treat various medical conditions. The contract has a period of performance through March 28, 2023. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a $35,574.58 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of XIFAXAN 550 MG TABLET 60S, a medical product, with a period of performance through February 14, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award has an ultimate completion date of June 10, 2024 and a ceiling value of $4,642.33. The contract is for the supply of XIFAXAN 550 mg tablets. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This is a $34,214.04 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, which has no set-aside designation, is for the provision of XIFAXAN 550 mg tablets to support military and federal medical institutions. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for supplying a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,433.80 firm-fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a medication used for the treatment of various medical conditions. The contract has an ultimate completion date of July 5, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,710.15 firm fixed-price contract is for the delivery of XIFAXAN 550 MG TABLET UD 60S, a prescription medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical division. This IDC serves as a primary vehicle for...
This $157,381.89 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999, which serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of medical commodities to support...
This is a $35,539.54 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of XIFAXAN 550 MG TABLET 60S, a medication used for various medical conditions. The contract has an ultimate completion date of July 1, 2024 and was awarded on June 28, 2024. This contract award is not designated as a set-aside. In addition to this...
This is a $13,639.61 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of XIFAXAN 550 MG TABLET 60S, a medical product with the Federal Supply Code 4564897853. This contract is not designated as a set-aside. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,747.00 firm fixed-price delivery order is for the supply of XIFAXAN 550 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of February 14, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB25FM8R3
    Delivery Order

This is a $2,414.88 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of XIFAXAN 550 MG TABLET 60S, a prescription medication, with a period of performance through February 2025.

Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies for military personnel, veterans, and other federal beneficiaries. The contract award reviewed was not designated with any set-aside requirements, indicating open competition.

Generated 5/28/25, 10:46 AM